Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

An established 5858-year-old male patient comes to the primary care clinic to review his recent laboratory results. Four weeks prior, he was noted to have a blood pressure of 154/92154/92 mmHg and persistent microalbuminuria. At that time, lisinopril therapy was prescribed. During today's visit, he reports feeling well without any dizziness, peripheral edema, or changes in urinary output. His current blood pressure is 128/78128/78 mmHg. A comparison of his laboratory panels is provided below:

ParameterFour Weeks AgoCurrent Visit
Blood urea nitrogen1616 mg/dL2222 mg/dL
Serum creatinine1.21.2 mg/dL1.51.5 mg/dL
Serum potassium4.14.1 mEq/L4.84.8 mEq/L

Which of the following is the most appropriate next step in the management of this patient?

  1. Maintain the present dosage of lisinopril and schedule routine follow-upCevap
  2. B
    Halt lisinopril therapy and begin treatment with amlodipine
  3. C
    Discontinue lisinopril and substitute with valsartan
  4. D
    Obtain a bilateral renal artery duplex ultrasound
  5. E
    Add spironolactone to provide additional renal protection

Cevap

Maintain the present dosage of lisinopril and schedule routine follow-up.
The correct course of action is to maintain the present dosage of lisinopril and schedule a routine follow-up. ACE inhibitors prevent the conversion of Angiotensin I to Angiotensin II. Because Angiotensin II normally preferentially constricts the efferent arteriole of the glomerulus, blocking its action leads to efferent arteriolar vasodilation. This lowers intraglomerular hydrostatic pressure, which is highly beneficial for slowing the progression of diabetic nephropathy. However, the drop in intraglomerular pressure correspondingly causes a mild decrease in the Glomerular Filtration Rate (GFR), which manifests clinically as an acute increase in serum creatinine. Clinical guidelines establish that an increase in serum creatinine of up to 30%30\% from baseline within the first several weeks of initiating an ACE inhibitor or ARB is a safe, expected hemodynamic response. In this patient, the creatinine increased from 1.21.2 mg/dL to 1.51.5 mg/dL, which is exactly a 25%25\% increase. Since his potassium remains within the normal range (4.84.8 mEq/L) and his blood pressure is well controlled, the medication should be continued to preserve its renoprotective benefits.

Adım Adım Çözüm

1
Evaluate the magnitude of the serum creatinine increase from the baseline laboratory values.
The serum creatinine rose from 1.21.2 mg/dL to 1.51.5 mg/dL, which represents exactly a 25%25\% absolute increase.
Guidelines state that a rise in serum creatinine of ≤30%\leq 30\% following the initiation of an ACE inhibitor or ARB is a normal and acceptable physiologic response.
2
Assess the serum potassium level and overall clinical status to ensure there are no life-threatening complications.
The patient's potassium is 4.84.8 mEq/L (within normal limits), and his blood pressure has successfully improved to 128/78128/78 mmHg without hypotensive symptoms.
Significant hyperkalemia (>5.5> 5.5 mEq/L) or symptomatic hypotension would necessitate a dose reduction or discontinuation of the therapy.
3
Determine the appropriate management intervention based on the physiological interpretation of the labs.
Because the laboratory changes reflect expected efferent arteriolar vasodilation rather than acute tubular necrosis or true kidney injury, no changes to the medication are required.
Continuing the current medication allows the patient to maintain the cardiovascular and renoprotective benefits of ACE inhibition.

Anahtar Kavram

Monitoring ACE inhibitor therapy initiation
Bu soruyu puanla